1. Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit
- Author
-
Kumar Singh Saikatendu, Michael J. Sofia, Matthew D. Disney, David Baker, Jennifer O. Nwankwo, Marla Weetall, Annaliesa S. Anderson, Christopher P. Austin, Mindy I. Davis, Matthias Götte, Emmie de Wit, Andrew D. Mesecar, Matthew D. Hall, Richard J. Whitley, Stephanie Moore, James M. Anderson, Kara Carter, George R. Painter, Anthony J. Conley, Charlotte A. Lanteri, Sandra K. Weller, Jay Bradner, Celia A. Schiffer, Tomas Cihlar, Abigail Grossman, Timothy P. Sheahan, Kizzmekia S. Corbett, Stephanie L. Ford-Scheimer, Kyle R. Brimacombe, Lillian Chiang, Elizabeth A. Campbell, Daria J. Hazuda, Mark R. Denison, Frederick G. Hayden, Sara Cherry, Pei Yong Shi, Courtney V. Fletcher, Hilary D. Marston, Jules O'Rear, Hugh D. C. Smyth, Francis S. Collins, and Anthony S. Fauci
- Subjects
0301 basic medicine ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,medicine.disease_cause ,NIH Virtual SARS-CoV-2 Supplement ,03 medical and health sciences ,0302 clinical medicine ,Research community ,preclinical ,Immunology and Allergy ,Medicine ,State of the science ,Coronavirus ,Medical education ,geography ,Summit ,geography.geographical_feature_category ,SARS-CoV-2 ,business.industry ,Research needs ,antiviral therapeutics ,viral replication machinery ,emerging modalities ,AcademicSubjects/MED00290 ,030104 developmental biology ,Infectious Diseases ,Drug development ,proteases ,business ,030217 neurology & neurosurgery - Abstract
The NIH Virtual SARS-CoV-2 Antiviral Summit, held on 6 November 2020, was organized to provide an overview on the status and challenges in developing antiviral therapeutics for coronavirus disease 2019 (COVID-19), including combinations of antivirals. Scientific experts from the public and private sectors convened virtually during a live videocast to discuss severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) targets for drug discovery as well as the preclinical tools needed to develop and evaluate effective small-molecule antivirals. The goals of the Summit were to review the current state of the science, identify unmet research needs, share insights and lessons learned from treating other infectious diseases, identify opportunities for public-private partnerships, and assist the research community in designing and developing antiviral therapeutics. This report includes an overview of therapeutic approaches, individual panel summaries, and a summary of the discussions and perspectives on the challenges ahead for antiviral development.
- Published
- 2021
- Full Text
- View/download PDF